ETX.L Share News (ETX)

ETX.L Information

There is currently no data for ETX

Chairman's wife buys Redrow shares

Tue, 02nd Mar 2010 16:33

Redrow chairman Steve Morgan's wife has bought 100,000 shares in the housebuilder taking their combined stake to 29.95%. Fiona Morgan paid 131.5p a share for the 100,000 shares. The total cost was £131,500. Morgan founded Redrow in 1974 and floated the company 20 years later. He also owns Wolverhampton Wanderers Football Club, whose squad includes former Gillingham FC winger Matt Jarvis. Last week, Redrow reported a 25% increase in interim revenues to £187.2m. The reported loss fell by 81% to £8.7m in the six months to December 2009. Last autumn, Redrow raised £150m from a 13-for-14 rights issue at 105p a share. Net debt was £49.3m at the end of 2009. The net asset value is 141p a share. Redrow says it has the appropriate capital structure in place but the market remains fragile. Top Director BuysRedrow (RDW) Director name: Mr Steve MorganAmount purchased: 100,000 @ 131.50p Value: £131,500Informa (INF) Director name: Mr Adam WalkerAmount purchased: 22,000 @ 350.89p Value: £77,196WSP Group (WSH) Director name: Mr Peter R GillAmount purchased: 24,833 @ 279.78p Value: £69,478Education Development International (EDD) Director name: Mr Richard PriceAmount purchased: 50,000 @ 136.00p Value: £68,000Absolute Return Trust GBP Shares (ABR) Director name: Mr Robin RumbollAmount purchased: 25,000 @ 119.00p Value: £29,750e-Therapeutics (ETX) Director name: Mr John CordinerAmount purchased: 67,376 @ 40.50p Value: £27,287Goals Soccer Centres (GOAL) Director name: Mr Graham WilsonAmount purchased: 10,000 @ 150.00p Value: £15,000RM Group (RM.) Director name: Mr Rob SirsAmount purchased: 8,194 @ 173.25p Value: £14,196Brewin Dolphin (BRW) Director name: Mr Jamie MathesonAmount purchased: 11,379 @ 121.00p Value: £13,769Brit Insurance Holdings NV (BRE) Director name: Mr Kenneth CulleyAmount purchased: 1,647 @ 739.13p Value: £12,173Top Director SellsDiageo (DGE) Director name: Mr Paul S WalshAmount sold: 99,000 @ 1,088.00p Value: £1,077,120Rio Tinto (RIO) Director name: Mr Guy R ElliottAmount sold: 19,495 @ 3,460.00p Value: £674,527Intercede Group (IGP) Director name: Mr Richard Arthur ParrisAmount sold: 1,000,000 @ 42.50p Value: £425,000Carnival (CCL) Director name: Mr Peter RatcliffeAmount sold: 11,465 @ 2,262.58p Value: £259,405Education Development International (EDD) Director name: Sir Bryan NicholsonAmount sold: 250,000 @ 136.00p Value: £340,000RSA Insurance Group (RSA) Director name: Mr George CulmerAmount sold: 211,883 @ 128.07p Value: £271,359Rathbone Brothers (RAT) Director name: Mr Richard P LanyonAmount sold: 20,000 @ 825.00p Value: £165,000Bunzl (BNZL) Director name: Mr Patrick LarmonAmount sold: 23,504 @ 691.11p Value: £162,438Bunzl (BNZL) Director name: Mr Brian MayAmount sold: 20,542 @ 691.11p Value: £141,968Centrica (CNA) Director name: Mr Mark HanafinAmount sold: 41,657 @ 282.30p Value: £117,598

More News

16 Oct 2013 11:57

UK WINNERS & LOSERS: Hargreaves Continues To Rise, e-Therapeutics Trips

16 Oct 2013 08:56

e-Therapeutics Pretax Loss Widens As R&D Expenditure Rises

30 Sep 2013 18:45

DIRECTOR DEALINGS: E-Therapeutics Exec, Wife Combined Shares Total 1.8M

24 Jul 2013 15:53

Wife of DS Smith CEO sells 5.6m-pound stake

The wife of DS Smith frontman Miles Roberts sold a substantial sum of shares in the packaging and office supplies firm on the same day it was revealed the Chief Executive Officer (CEO) received a big pay increase last year. The move came on Tuesday, the same day DS Smith released its annual report

14 May 2013 09:46

e-Therapeutics pleases with pipeline progress

News from biotech company e-Therapeutics about the progress of two clinical trials for its cancer drug pleased the markets on Tuesday. The AIM-listed company provided first findings for the company's ETS2101 drug candidate in Phase I trials in the US for patients with brain cancer and in the UK fo

14 May 2013 08:04

Tuesday broker round-up UPDATE

Babcock International: Jefferies increases target price from 1080p to 1250p and maintains a buy recommendation. Barratt Developments: Bank of America takes target price from 265p to 325p, while downgrading to neutral. Belgravium Technologies: WH Ireland places both its target price and its neutral

10 May 2013 07:14

Friday broker round-up UPDATE

Afren: Westhouse Securities initiates with a target price of 160p and a buy recommendation. Ashmore Group: Credit Suisse raises target price from 375p to 440p upgrading from underperform to neutral. Barratt Developments: Citigroup increases target price from 245p to 315p leaving its neutral rating

19 Feb 2013 16:21

Debenhams Executive Director adds to stake

Michael Sharp, the Executive Director of retail chain Debenhams, has topped up his stake in the group with the purchase of 50,000 shares. Sharp, who has been in his current role since September 2011, bought the shares at 97.20p for a total of £48,598. He now holds 6.2m shares in the company. Debe

11 Feb 2013 09:15

e-Therapeutics shares jump following 40m equity issue

Drug discovery and development company e-Therapeutics is proposing to raise 40m pounds through an issue of new ordinary shares to existing and new institutional investors. The new shares will be priced at 32p, a premium of 4.0% to the closing mid-market price on Friday. Following the proposed issu

23 Oct 2012 09:23

Tuesday broker round-up

Aggreko: UBS cuts target from 2,750p to 2,550p, buy rating kept. ARM Holdings: Investec keeps buy rating and 800p target. Avacta: Panmure Gordon keeps buy rating and 1.75p target. AZ Electronic: Canaccord Genuity ups target from 360p to 376p, buy rating kept. Babcock: JPMorgan Cazenove ups targe

22 Oct 2012 08:19

Monday broker round-up - UPDATE

888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept. Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barcl

22 Oct 2012 07:53

e-therapeutics produces mixed interims

e-therapeutics, a drug discovery and development company, produced mixed interims with slightly increased losses, but reported progress on its lead cancer drug. As expected, first half losses increased to £1.8m (2011: loss of £1.5m), reflecting increased investment in the business. The company ha

15 Mar 2011 17:05

Bramson vehicle buys more shares in F&C

F&C Asset Management chairman Edward Bramson's investment vehicle SIGA LP has acquired more shares in the asset management company. Bramson was appointed chairman of F&C last month after a shareholder coup removed the previous incumbent, along with another non-executive, and appointed three new di

14 Mar 2011 17:19

Wife of outgoing FD sells British Land shares

Diane Roberts, the wife of British Land finance director Graham Roberts, has raised more than £1m by selling more than three-quarters of the couple's stake in the property investor. She sold 191,780 shares at 562.8p each, which raised £1.08m. The couple are left with 50,464 shares in British Land.

4 Mar 2011 17:03

Shaftesbury boss invests £100,000

Shaftesbury chief executive Jonathan Lane has invested a further £100,000 in the property investor. Lane has bought 22,222 shares at 450p each. That takes his stake to 966,233 shares, which is worth £4.3m at the latest purchase price. Lane raised just over £99,000 from the sale of option shares la

Latest Share Chat

ETX.L Share News (ETX)

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Chairman's wife buys Redrow shares

Login to your account

Quickpicks are a member only feature

Login to your account